Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4210730 | 0.87 | ALDH1A1 (0.52) | GAAPOLBALDH1A1KDM4ETDP1 | |
| SCHEMBL17549763 | 0.85 | MAPK1 (0.63) | GAAPOLBALDH1A1KDM4ETDP1 | |
| SCHEMBL19962677 | 0.85 | GAA (0.70) | GAAPOLBALDH1A1KDM4ECYP1A2 | |
| SCHEMBL2963432 | 0.84 | CYP2C19 (0.56) | GAAPOLBALDH1A1KDM4ETDP1 | |
| SCHEMBL10690898 | 0.81 | ALDH1A1 (0.54) | GAAPOLBALDH1A1KDM4ETDP1 | |
| SCHEMBL7219667 | 0.81 | ALDH1A1 (0.54) | GAAPOLBALDH1A1KDM4ETDP1 | |
| SCHEMBL14803772 | 0.81 | KMT2A (0.59) | GAAPOLBALDH1A1KDM4ETDP1 | |
| SCHEMBL7217728 | 0.80 | ALDH1A1 (0.52) | GAAPOLBALDH1A1KDM4ETDP1 | |
| SCHEMBL7223234 | 0.80 | ALDH1A1 (0.52) | GAAPOLBALDH1A1KDM4ETDP1 | |
| SCHEMBL12243012 | 0.80 | SMN1; SMN2 (0.68) | GAAPOLBALDH1A1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBVIE, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8350083-B2 | Antagonists of the TRPV1 receptor and uses thereof | ABBVIE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2450346-A1 | Antagonists of the TRPV1 receptor and uses thereof | Abbott Laboratories (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| US-8030504-B2 | Pain, especially, inflammatory hyperalgesia, ostheoarthritic pain, chronic lower pain, allodynia, migraine. Methods of controlling pain and treating bladder overactivity and urinary incontinence | ABBOTT LABORATORIES (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2134678-A2 | N-(5, 6, 7, 8-TETRAHYDRONAPHTHALEN-1-YL) UREA DERIVATIVES AND RELATED COMPOUNDS AS TRPV1 VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | Abbott Laboratories (US) | 2009-12-23 | — | — | EP | disclosed |
| CN-101563318-A | N- (5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain | ABBOTT LAB (US) | 2009-10-21 | — | — | CN | disclosed |
| WO-2008079683-A2 | N- (5, 6, 7, 8-TETRAHYDRONAPHTHALEN-1-YL) UREA DERIVATIVES AND RELATED COMPOUNDS AS TRPV1 VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | GAA 4072/4885POLB 4834/4885ALDH1A1 1142/4885 |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | GAA 4177/4885POLB 4821/4885ALDH1A1 1242/4885 |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | GAA 4072/4885POLB 4834/4885ALDH1A1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.